Published in Clin Pharmacol Ther on September 01, 1984
Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol (1986) 1.48
Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol (1994) 0.91
Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol (1985) 0.90
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Drug Metab Dispos (2006) 0.83
Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br J Clin Pharmacol (1986) 0.80
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J (1969) 4.21
DREAM is a Ca2+-regulated transcriptional repressor. Nature (1999) 3.54
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Developmental switch of CREM function during spermatogenesis: from antagonist to activator. Nature (1992) 2.78
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med (1978) 2.68
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46
Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther (1971) 2.45
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand (1976) 2.34
Rapid gas-liquid chromatographic estimation of antipyrine in plasma. J Pharm Pharmacol (1973) 2.31
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J (1971) 2.19
Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J (1970) 2.13
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07
Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci (1967) 2.05
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther (1985) 1.87
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Cardiac arrest after interscalene brachial plexus block with ropivacaine and lidocaine. Acta Anaesthesiol Scand (2003) 1.83
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther (1998) 1.72
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis (2008) 1.69
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers. Eur J Clin Pharmacol (1974) 1.68
Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med (1965) 1.67
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther (1992) 1.66
Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations. J Med Genet (1971) 1.66
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun (1999) 1.66
Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet (1986) 1.63
Debrisoquine hydroxylation polymorphism and personality. Lancet (1989) 1.62
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem (2001) 1.57
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry (1981) 1.52
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit (1990) 1.50
Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol (1986) 1.48
High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet (1982) 1.46
Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther (1993) 1.46
Hypothermic effect of apomorphine in the mouse. J Pharm Pharmacol (1972) 1.43
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet (1978) 1.42
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin Pharmacokinet (1977) 1.41
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther (1989) 1.41
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther (1992) 1.41
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37
Drug utilization 90%--a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol (1998) 1.35
New possibilities for adrenergic modulation of ganglionic transmission. Pharmacol Rev (1966) 1.32
Induction of CREM activator proteins in spermatids: down-stream targets and implications for haploid germ cell differentiation. Mol Endocrinol (1993) 1.31
Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31
Clinical pharmacology and primary health care in Europe--a gap to bridge. The WHO Working Group on Clinical Pharmacology in Europe. Eur J Clin Pharmacol (1990) 1.30
The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1975) 1.30
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther (2008) 1.29
Compliance with good practice in prescription writing at outpatient clinics in Saudi Arabia. East Mediterr Health J (2006) 1.29
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol (1995) 1.28
Functional kainate-selective glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci U S A (1993) 1.27
Indole-3-acetic acid in human cerebrospinal fluid: identification and quantification by mass fragmentography. Science (1972) 1.27
Methylation of mercury compounds by methylcobalamin. Biochemistry (1971) 1.27
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol (1996) 1.26
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther (2001) 1.25
Clinical pharmacology and the provision of drug information. Eur J Clin Pharmacol (1992) 1.25
"Serotonin depression"--a biochemical subgroup within the affective disorders? Science (1976) 1.24
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol (1976) 1.23
Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. Trop Med Parasitol (1986) 1.22
Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol (1985) 1.22
Determination of chloroquine and its desethyl metabolite in whole blood: an application for samples collected in capillary tubes and dried on filter paper. Ther Drug Monit (1985) 1.21
Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol (1983) 1.21
Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol (1975) 1.20
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol (1987) 1.20
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure. Br Med J (1976) 1.20
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics (1995) 1.20
Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol (1985) 1.18
Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics (1993) 1.16
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 1.16
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther (2011) 1.15
Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet (1981) 1.14
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis (2004) 1.14
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13